The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes ...

A research team from Great Britain identified factors, such as mental health issues, lack of diabetic eye screening awareness, and transport difficulties, that interfere with attendance at annual ...

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three biosimilar candidates from Celltrion, including a biosimilar for reference ...

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology. EssilorLuxottica has ...